Compare FWRD & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | BNTC |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.5M | 454.2M |
| IPO Year | 2024 | 2020 |
| Metric | FWRD | BNTC |
|---|---|---|
| Price | $15.97 | $12.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $37.50 | $27.67 |
| AVG Volume (30 Days) | ★ 1.1M | 140.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.54 | 80.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,269,573,000.00 | N/A |
| Revenue This Year | $6.57 | N/A |
| Revenue Next Year | $6.66 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.86 | $9.85 |
| 52 Week High | $32.47 | $16.76 |
| Indicator | FWRD | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 43.15 |
| Support Level | $15.28 | $11.40 |
| Resistance Level | $23.55 | $12.01 |
| Average True Range (ATR) | 1.04 | 0.80 |
| MACD | 0.16 | -0.19 |
| Stochastic Oscillator | 97.44 | 15.98 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in North and South America, Europe, and Asia.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.